Brenus Pharma Paul Bravetti (PharmD, HEC Paris) is a strategic executive with a particular interest in scientific innovation and entrepreneurial adventures.
With his international experience in major pharmaceutical companies, which has shaped his understanding of the biopharmaceutical industry, he has successfully led the launches of therapeutics in immuno-oncology and biomolecular diagnostics across Europe and Asia. He joined Brenus Pharma in 2020 and became Chief Executive Officer in 2022 with a clear vision, mission, and leadership to address current unmet needs and make a significant impact for cancer patients.”
Brenus Pharma is a French clinical-stage biotech developing a pioneering technology platform, Stimulated-Tumor-Cell (STC).
STC is designed to generate ‘off-the-shelf’ and ‘first-in-class’ therapeutic cancer vaccine leading the way to a new precision medicine in immuno-oncology.
Brenus Pharma is on the brink of a breakthrough and will start its first-in-human study in 2024 in colorectal cancer, 2nd cause of cancer-related deaths worldwide.
We are building a strong portfolio in solid tumors, leveraging our patented STC platform, to change a paradigm in oncology.
